Energous partner NewSound wins FCC approval for hearing aid - Mass Device

-

Energous (NSDQ:WATT) announced today that its partner NewSound received FCC approval for its WattUp-enabled Primo W hearing aid.

NewSound Primo W, a next-generation hearing aid, utilizes Energous’ WattUp radio frequency-based wireless charging technology, which supports small, rounded devices such as behind-the-ear and in-the-ear hearing aids, according to a news release.

Along with hassle-free battery recharging, the next-generation device includes flexible drop-to-charge design for ease of use, lithium battery support with up to 20 hours of working time, Soundware App control for battery status, self-hearing checks, program management, remote-fit and more, plus an all-in-one case for storage, charging, UV sanitizing and dehumidifying.

“The Primo W hearing aid represents a new level of technical advancement offering full Bluetooth control in conjunction with Dialog BLE and further validates the continued progress of the Energous wireless charging 2.0 technology, which offers substantial improvements over 1st generation, coil-based charging technologies in terms of freedom of movement, communications and control,” Energous president & CEO Stephen Rizzone said in the release. “We anticipate the announcement of additional WattUp-enabled products in both the hearable and sensor markets, further demonstrating RF-based wireless power transfer is gaining meaningful traction.”

“Securing FCC approval for our Primo W hearing aid solution is a major milestone along our journey to providing our customers with best-in-class hearing products that amplify their hearing experience,” added NewSound CTO Boyang Li. “The Primo W powered by Energous’ WattUp wireless charging technology enhances the experience for users and it represents the next generation of hearing aids.”



Comments

Post a Comment

Popular posts from this blog

Well-liked Medicare plan vs. higher-ranked providers - ChicagoNow

-
Image
Medicare Open Enrollment ends December 7. The easy choice is to stay with all-in-one Medicare Advantage instead of switching to Traditional Medicare plus a supplement and drug plan. The hard one is whether to switch between Medicare Advantage plans, from a well-liked one to one accepted at a so-called top-10 hospital. Humana Gold Plus, a Medicare Advantage HMO, has served me well for five years. Hearing aids cost me only $10 after its $2,000 allowance. Routine doctor and dentist appointments and my medication cost nothing. But Humana Gold Plus is not accepted by Northwestern Memorial Hospital, the nearby hospital that US News & World Report ranks as the tenth best in the country, or by Northwestern Medicine physicians. My primary care physician is in an Advocate Medical Group. If I were hospitalized, it would be at Advocate Illinois Masonic Medical Center. If I had a serious illness, I’d see specialists in Advocate’s network. Illinois Masonic is not a second-rate hospital, and
Read more

Minnesota veterans blame 3M's 'defective' ear plugs for hearing damage - KSTP

-
Image
3M did not admit any wrongdoing as part of that settlement. Read 3M's full statement on the ear plugs here. "We deny this product was defectively designed," a company spokesperson said in a statement to 5 INVESTIGATES, adding they will "defend against the allegations in these lawsuits." More than 630 lawsuits have been filed and will be heard in a federal court in Florida. An attorney involved with the multi-district litigation says roughly 30 have been filed by veterans who live in Minnesota. Constant ringing Sarah Kay Carlson, an Army veteran from St. Paul, filed her lawsuit in April, claiming 3M exposed her and thousands of other Marines and soldiers to "extremely dangerous and disabling noise." 3M Earplug Complaint (Sarah Kay Carlson) Ramsey County (Filed) (PDF) 3M Earplug Complaint (Sarah Kay Carlson) Ramsey County (Filed) (Text) Carlson, who was deployed as part of Operation Iraqi Freedom in the late 2000s, provided security to convoys t
Read more

Sickle Cell Disease (SCD): Practice Essentials, Background, Genetics

-
Image
hemophilia c factor 11 :: Article Creator Regeneron Reports Fourth Quarter And Full Year 2023 Financial And Operating Results Fourth quarter 2023 revenues increased 1% to $3.43 billion versus fourth quarter 2022; excluding RonapreveTM(a)(b), revenuesincreased 14% Full year 2023 revenues increased 8% to $13.12 billion versus full year 2022;excluding Ronapreve(a), revenuesincreased 12% Fourth quarter 2023 Dupixent®global net sales(recorded by Sanofi) increased 31% to $3.22 billion versus fourth quarter 2022; full year 2023 Dupixent global net sales increased 33% to $11.59 billion versus 2022 Fourth quarter 2023 U.S. Net sales for EYLEA®HD and EYLEA®were $1.46 billion, including $123 million from EYLEA HD; full year 2023 U.S. Net sales for EYLEA HD and EYLEA were $5.89 billion, including $166 million from EYLEA HD following its August 2023 FDA approval Fourth quarter 2023 Libtayo®global n
Read more